To review the pharmacodynamic and clinical activities of Daflon 500 mg.
Data selection:
Choice of relevant publications in the literature.
Conclusion:
The pharmacological activities of Daflon 500 mg on capillary hyperpermeability, inflammatory mediators and lymphatic drainage can explain its therapeutic efficacy in the treatment of chronic venous insufficiency.
AmielM, BarbeR.Etude de de'lai et de la durée d'action du Daflon 500 mg. J Int Med1987;85 (suppl):19-21.
2.
TsouderosY.Are the phlebotonic properties shown in clinical pharmacology predictive of a therapeutic benefit in chronic venous insufficiency? Our experience with Daflon 500 mg. Inter Angio1989;8 (Suppl 4):53-9.
3.
CospiteM.Double-blind study of pharmacodynamic and clinical activities of Daflon 500 mg in venous insufficiency. Advantages of the new micronized form. Inter Angio1989;8 (Suppl 4):61-5.
4.
LabridC.Poprietes pharmacologique de Daflon 500 mg. J Int Med1987;85 (suppl):30-5.
5.
DamonM. Effect of chronic treatment with a purified flavonoid fraction on inflammatory granuloma in the rat. Study of prostaglandin E2 and F2-alpha and thromboxane B2 release and histological changes. Arzneim Forsch/Drug Res1987;37(II) 10:1149-53.
6.
DuhaultJ.Mécanisme d'action de Daflon 500 mg sur le tonus veineux. Artères Veines1992;11(4):217-8.
7.
Di PerriT, AuteriA.Action of S 5682 on the complement system. In vivo and in vitro studies. Inter Ango1988; (Suppl 2):11-15.
8.
CotonatJ, CotonatMD.Lymphagogue and pulsatile activities of Daflon 500 mg on canine thoracic lymph duct. Inter Angio1989;8(Suppl 4):15-8.
